← All comparisons

Semaglutide vs Tirzepatide

Last updated

The key difference

Both are approved once-weekly injections for type 2 diabetes and obesity. Semaglutide activates the GLP-1 receptor; tirzepatide activates both the GIP and GLP-1 receptors. In the SURMOUNT-5 head-to-head trial in adults with obesity, average weight loss at 72 weeks was 20.2% with tirzepatide versus 13.7% with semaglutide.

Side by side

What it is
SemaglutideA long-acting GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Among the most effective approved weight-loss therapies.
TirzepatideA dual GIP and GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and weight management (Zepbound), with weight-loss results that often exceed GLP-1-only agents.
Research status
SemaglutideClinical
TirzepatideClinical
Category
SemaglutideWeight & Metabolic
TirzepatideWeight & Metabolic
Half-life
SemaglutideApproximately 7 days (once-weekly dosing)
TirzepatideApproximately 5 days (once-weekly dosing)
Routes
Semaglutidesubcutaneous, oral
Tirzepatidesubcutaneous
Reported dosing
SemaglutideClinical regimens titrate from 0.25 mg weekly up to 2.4 mg weekly (Wegovy) over several weeks to limit GI effects. Stated as labeled clinical dosing.
TirzepatideClinical regimens titrate from 2.5 mg weekly up to 15 mg weekly over several months to manage GI tolerability. Stated as labeled clinical dosing.
Studied for
Semaglutide
  • Significant, sustained weight loss in clinical trials
  • Improves glycemic control in type 2 diabetes
  • Reduces cardiovascular events in high-risk patients
  • Increases satiety and reduces appetite
Tirzepatide
  • Substantial weight loss, often exceeding GLP-1-only agents
  • Strong improvement in glycemic control
  • Dual incretin action (GIP + GLP-1)
  • Improves lipid and metabolic markers
Side effects
Semaglutide
  • Nausea, vomiting, and diarrhea (especially during titration)
  • Constipation and abdominal discomfort
  • Risk of pancreatitis (uncommon)
  • Gallbladder issues with rapid weight loss
Tirzepatide
  • Nausea, vomiting, and diarrhea (especially during titration)
  • Decreased appetite and constipation
  • Risk of pancreatitis (uncommon)
  • Gallbladder issues with rapid weight loss
Cited studies
Semaglutide5 on its page
Tirzepatide4 on its page

How Semaglutide works

Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone glucagon-like peptide-1, enhancing glucose-dependent insulin secretion and suppressing glucagon. It slows gastric emptying and acts on hypothalamic appetite centers to increase satiety and reduce food intake. Fatty-acid acylation extends its half-life to roughly one week, enabling once-weekly subcutaneous dosing.

Full Semaglutide profile →

How Tirzepatide works

Tirzepatide is a single peptide that activates both the GIP and GLP-1 incretin receptors. GLP-1 agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite, while GIP agonism is thought to further improve insulin sensitivity and lipid metabolism. This dual incretin action produces robust glycemic and weight effects, with fatty-acid acylation enabling once-weekly dosing.

Full Tirzepatide profile →

Dosing shown is what research and community sources report, not a recommendation. For educational and research purposes only; not medical advice. How we source this

PeptideChat is for educational and research purposes only. Nothing on this site constitutes medical advice. Peptides are sold as research chemicals only and are not intended for human use. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. PeptideChat is an independent educational resource — not a pharmacy, compounding, or 503A/503B outsourcing facility — and does not sell products or provide medical advice.